nach oben

Die Radiologie

Erschienen in:

11.02.2022 | Magnetresonanztomografie | Leitthema

Klinische Bedeutung der neuen S3-Leitlinie zum hepatozellulären und biliären Karzinom für die Praxis

verfasst von: Sabrina Voesch, M. Bitzer, N. Malek

Erschienen in: Die Radiologie | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

In der neuen S3-Leitlinie „Diagnostik und Therapie des hepatozellulären Karzinoms und biliärer Karzinome“ wurde die Leitlinie des hepatozellulären Karzinoms (HCC) umfassend überarbeitet und erstmals um die biliären Karzinomen ergänzt. In den letzten Jahren wurden viele Studien zur Verbesserung der diagnostischen und therapeutischen Optionen durchgeführt. Einen besonderen Stellenwert in dieser Leitlinie nehmen sowohl beim HCC als auch beim intrahepatischen Cholangiokarzinom bei der Diagnostik die Magnetresonanztomographie (MRT) und die Biopsie ein. Im Bereich der therapeutischen Optionen wurden beim hepatozellulären Karzinom Fortschritte im Bereich der Lebertransplantation sowie Bridging und Downstaging in der Leitlinie abgebildet. Beim Cholangiokarzinom fällt neben den interventionellen Therapieoptionen und der Operation besonderes Gewicht auf die molekulare Diagnostik und die sich hieraus ergebenden Möglichkeiten für eine zielgerichtete Tumortherapie.

Globocan (2020) Population

AWMF (2021) Diagnostik und Therapie des hepatozellulären Karzinoms und biliärer Karzinome

Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP (2007) Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 5(8):938–945–945.e91–4CrossRef

Sangiovanni A, Prati GM, Fasani P et al (2006) The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 43(6):1303–1310PubMedCrossRef

Yuen MF, Tanaka Y, Fong DY et al (2009) Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 50(1):80–88PubMedCrossRef

Kanwal F, Kramer JR, Mapakshi S et al (2018) Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology 155(6):1828–1837.e2PubMedCrossRef

Simeone JC, Bae JP, Hoogwerf BJ et al (2017) Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clin Epidemiol 9:679–688PubMedPubMedCentralCrossRef

Inoue M, Yoshimi I, Sobue T, Tsugane S (2005) Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. JNCI J Natl Cancer Inst 97(4):293–300PubMedCrossRef

Bravi F, Bosetti C, Tavani A et al (2007) Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology 46(2):430–435PubMedCrossRef

10.

Aleksandrova K, Bamia C, Drogan D et al (2015) The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European prospective investigation into cancer and nutrition. Am J Clin Nutr 102(6):1498–1508PubMedPubMedCentralCrossRef

11.

Setiawan VW, Wilkens LR, Lu SC, Hernandez BY, Le Marchand L, Henderson BE (2015) Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 148(1):118–125 (quiz e115)PubMedCrossRef

12.

Cabibbo G, Celsa C, Calvaruso V et al (2019) Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol 71(2):265–273PubMedCrossRef

13.

Dang H, Yeo YH, Yasuda S et al (2020) Cure with interferon-free direct-acting antiviral is associated with increased survival in patients with hepatitis C virus-related hepatocellular carcinoma from both east and west. Hepatology 71(6):1910–1922PubMedCrossRef

14.

Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR (2009) High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 50(1):158–164PubMedCrossRef

15.

Rizvi S, Gores GJ (2013) Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145(6):1215–1229PubMedCrossRef

16.

Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA (2020) Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol 72(1):95–103PubMedCrossRef

17.

Sun HY, Lee JM, Shin CI et al (2010) Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (〈 or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 45(2):96–103PubMedCrossRef

18.

Haradome H, Grazioli L, Tinti R et al (2011) Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging. J Magn Reson Imaging 34(1):69–78PubMedCrossRef

19.

Inoue T, Kudo M, Komuta M et al (2012) Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT. J Gastroenterol 47(9):1036–1047PubMedCrossRef

20.

Granito A, Galassi M, Piscaglia F et al (2013) Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther 37(3):355–363PubMedCrossRef

21.

Maiwald B, Lobsien D, Kahn T, Stumpp P (2014) Is 3‑Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma? PLoS One 9(11):e111935PubMedPubMedCentralCrossRef

22.

Park VY, Choi JY, Chung YE et al (2014) Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT. Liver Int 34(10):1593–1602PubMedCrossRef

23.

Chen N, Motosugi U, Morisaka H et al (2016) Added value of a gadoxetic acid-enhanced hepatocyte-phase image to the LI-RADS system for diagnosing hepatocellular carcinoma. Magn Reson Med Sci 15(1):49–59PubMedCrossRef

24.

Tsurusaki M, Sofue K, Isoda H, Okada M, Kitajima K, Murakami T (2016) Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study. J Gastroenterol 51(1):71–79PubMedCrossRef

25.

Burrel M, Llovet JM, Ayuso C et al (2003) MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 38(4):1034–1042PubMedCrossRef

26.

Di Martino M, De Filippis G, De Santis A et al (2013) Hepatocellular carcinoma in cirrhotic patients: prospective comparison of US, CT and MR imaging. Eur Radiol 23(4):887–896PubMedCrossRef

27.

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64(6):1388–1402CrossRef

28.

Murakami T, Nakamura H, Tsuda K et al (1995) Contrast-enhanced MR imaging of intrahepatic cholangiocarcinoma: pathologic correlation study. J Magn Reson Imaging 5(2):165–170PubMedCrossRef

29.

Zhang H, Zhu J, Ke F et al (2015) Radiological imaging for assessing the respectability of hilar cholangiocarcinoma: a systematic review and meta-analysis. Biomed Res Int 2015:497942PubMedPubMedCentral

30.

Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD (2009) Liver biopsy. Hepatology 49(3):1017–1044PubMedCrossRef

31.

Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF (2008) Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 57(11):1592–1596PubMedCrossRef

32.

Müllhaupt B, Durand F, Roskams T, Dutkowski P, Heim M (2011) Is tumor biopsy necessary? Liver Transpl 17(2):S14–25PubMedCrossRef

33.

Fuks D, Cauchy F, Fusco G, Paradis V, Durand F, Belghiti J (2014) Preoperative tumour biopsy does not affect the oncologic course of patients with transplantable HCC. J Hepatol 61(3):589–593PubMedCrossRef

34.

Mazzaferro V, Llovet JM, Miceli R et al (2009) Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 10(1):35–43PubMedCrossRef

35.

Yao FY, Mehta N, Flemming J et al (2015) Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 61(6):1968–1977PubMedCrossRef

36.

Chapman WC, Garcia-Aroz S, Vachharajani N et al (2017) Liver transplantation for advanced hepatocellular carcinoma after downstaging without up-front stage restrictions. J Am Coll Surg 224(4):610–621PubMedCrossRef

37.

Mehta N, Guy J, Frenette CT et al (2018) Excellent outcomes of liver transplantation following down-staging of hepatocellular carcinoma to within Milan criteria: a multicenter study. Clin Gastroenterol Hepatol 16(6):955–964PubMedCrossRef

38.

Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67(1):358–380PubMedCrossRef

39.

Kulik L, Heimbach JK, Zaiem F et al (2018) Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis. Hepatology 67(1):381–400PubMedCrossRef

40.

Goldaracena N, Gorgen A, Sapisochin G (2018) Current status of liver transplantation for cholangiocarcinoma. Liver Transpl 24(2):294–303PubMedCrossRef

41.

Bridgewater J, Galle PR, Khan SA et al (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60(6):1268–1289PubMedCrossRef

42.

Sapisochin G, de Lope CR, Gastaca M et al (2014) Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study. Ann Surg 259(5):944–952PubMedCrossRef

43.

Le Roy B, Gelli M, Pittau G et al (2018) Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg 105(7):839–847PubMedCrossRef

44.

Xu Y, Shen Q, Wang N et al (2017) Microwave ablation is as effective as radiofrequency ablation for very-early-stage hepatocellular carcinoma. Chin J Cancer 36(1):14PubMedPubMedCentralCrossRef

45.

Chong CCN, Lee KF, Cheung SYS et al (2020) Prospective double-blinded randomized controlled trial of microwave versus radiofrequency ablation for hepatocellular carcinoma (mcRFA trial). HPB 22(8):1121–1127PubMedCrossRef

46.

Salem R, Gordon AC, Mouli S et al (2016) Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 151(6):1155–1163.e2PubMedCrossRef

47.

Kolligs FT, Bilbao JI, Jakobs T et al (2015) Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int 35(6):1715–1721PubMedCrossRef

48.

Raoul JL, Guyader D, Bretagne JF et al (1997) Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 26(5):1156–1161PubMed

49.

Pitton MB, Kloeckner R, Ruckes C et al (2015) Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 38(2):352–360PubMedCrossRef

50.

Lobo L, Yakoub D, Picado O et al (2016) Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: a systematic review and meta-analysis. Cardiovasc Intervent Radiol 39(11):1580–1588PubMedCrossRef

51.

Yang Y, Si T (2018) Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Cancer Biol Med 15(3):299–310PubMedPubMedCentralCrossRef

52.

Ludwig JM, Zhang D, Xing M, Kim HS (2017) Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus (90)Y-radioembolization for hepatocellular carcinoma. Eur Radiol 27(5):2031–2041PubMedCrossRef

53.

Casadei Gardini A, Tamburini E, Inarrairaegui M, Frassineti GL, Sangro B (2018) Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. Onco Targets Ther 11:7315–7321PubMedCrossRef

54.

Rim CH, Kim HJ, Seong J (2019) Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. Radiother Oncol 131:135–144PubMedCrossRef

55.

Rim CH, Kim CY, Yang DS, Yoon WS (2018) Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis and systematic review. Radiother Oncol 129(1):112–122PubMedCrossRef

56.

Ray CE Jr., Edwards A, Smith MT et al (2013) Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 24(8):1218–1226PubMedCrossRef

57.

Koch C, Franzke C, Bechstein WO et al (2020) Poor prognosis of advanced cholangiocarcinoma: real-world data from a tertiary referral center. Digestion 101(4):458–465PubMedCrossRef

58.

Gusani NJ, Balaa FK, Steel JL et al (2008) Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg 12(1):129–137PubMedCrossRef

59.

Boehm LM, Jayakrishnan TT, Miura JT et al (2015) Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol 111(2):213–220PubMedCrossRef

60.

Kiefer MV, Albert M, McNally M et al (2011) Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer 117(7):1498–1505PubMedCrossRef

61.

Vogl TJ, Naguib NN, Nour-Eldin NE et al (2012) Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: results and prognostic factors governing treatment success. Int J Cancer 131(3):733–740PubMedCrossRef

62.

Cucchetti A, Cappelli A, Mosconi C et al (2017) Improving patient selection for selective internal radiation therapy of intra-hepatic cholangiocarcinoma: a meta-regression study. Liver Int 37(7):1056–1064PubMedCrossRef

63.

Gangi A, Shah J, Hatfield N et al (2018) Intrahepatic cholangiocarcinoma treated with transarterial yttrium-90 glass microsphere radioembolization: results of a single institution retrospective study. J Vasc Interv Radiol 29(8):1101–1108PubMedPubMedCentralCrossRef

64.

Reimer P, Virarkar MK, Binnenhei M, Justinger M, Schon MR, Tatsch K (2018) Prognostic factors in overall survival of patients with unresectable intrahepatic cholangiocarcinoma treated by means of yttrium-90 radioembolization: results in therapy-naive patients. Cardiovasc Intervent Radiol 41(5):744–752PubMedCrossRef

65.

Yang L, Shan J, Shan L, Saxena A, Bester L, Morris DL (2015) Trans-arterial embolisation therapies for unresectable intrahepatic cholangiocarcinoma: a systematic review. J Gastrointest Oncol 6(5):570–588PubMedPubMedCentral

66.

Hyder O, Marsh JW, Salem R et al (2013) Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol 20(12):3779–3786PubMedCrossRef

67.

Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25–34PubMedCrossRef

68.

Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390PubMedCrossRef

69.

Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894–1905PubMedCrossRef

70.

Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126):1163–1173PubMedCrossRef

71.

Bruix J, Qin S, Merle P et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389(10064):56–66PubMedCrossRef

72.

Abou-Alfa GK, Meyer T, Cheng AL et al (2018) Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 379(1):54–63PubMedPubMedCentralCrossRef

73.

Zhu AX, Kang YK, Yen CJ et al (2019) Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α‑fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20(2):282–296PubMedCrossRef

74.

Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273–1281PubMedCrossRef

75.

Okusaka T, Nakachi K, Fukutomi A et al (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 103(4):469–474PubMedPubMedCentralCrossRef

76.

Lamarca A, Hubner RA, David Ryder W, Valle JW (2014) Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol 25(12):2328–2338PubMedCrossRef

77.

Abou-Alfa GK, Sahai V, Hollebecque A et al (2020) Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 21(5):671–684PubMedPubMedCentralCrossRef

78.

Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX (2017) New horizons for precision medicine in biliary tract cancers. Cancer Discov 7(9):943–962PubMedPubMedCentralCrossRef

79.

Bitzer M, Spahn S, Babaei S et al (2021) Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma. NPJ Precis Oncol 5(1):80PubMedPubMedCentralCrossRef

Titel: Klinische Bedeutung der neuen S3-Leitlinie zum hepatozellulären und biliären Karzinom für die Praxis
verfasst von: Sabrina Voesch
M. Bitzer
N. Malek
Publikationsdatum: 11.02.2022
Verlag: Springer Medizin
Schlagwörter: Magnetresonanztomografie
Hepatozelluläres Karzinom
Lebertransplantation
Lebertransplantation
Lebertransplantation
Hepatozelluläres Karzinom
Lebertransplantation
Lebertransplantation
Magnetresonanztomografie
Cholangiokarzinom
Cholangiokarzinom
Sorafenib
Onkologische Therapie
Erschienen in: Die Radiologie / Ausgabe 3/2022
Print ISSN: 2731-7048
Elektronische ISSN: 2731-7056
DOI: https://doi.org/10.1007/s00117-022-00970-3

Passend zum Thema

Synergien nutzen gegen Tumore

Magenkarzinom

Lungen- und Magentumore können dank Immuntherapien deutlich besser behandelt werden. Dennoch kommt es trotzdem weiterhin häufig zum Krankheitsprogress. Welche Therapieoptionen sich in der Zweitlinie am besten eignen, haben wir für Sie zusammengefasst.

Darmkrebsreihenuntersuchungen zeigen EU-weit Erfolge

Kolonkarzinom

In Europa haben viele Länder dem Darmkrebs mit Hilfe von Früherkennungsprogrammen den Kampf angesagt. Es gibt einen deutlichen Zusammenhang zwischen Inzidenz und Mortalität von Darmkrebs und der Zeitspanne seit Einführung von Reihenuntersuchungen.

GI-Tumore und die Rolle von Angiogenesehemmern

Content Hub

Entdecken Sie mit praxisrelevanten Patientenfällen, kompakten Studieninhalten, informativen Experteninterviews und weiteren spannenden Inhalten, wie Sie den vielseitigen Herausforderungen bei GI-Tumoren begegnen können. Hier erfahren Sie mehr! _{PP-RB-DE-2009}

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

Wiederkehrende Kopfschmerzen und Sehstörungen bei Veränderungen der weißen Substanz des Gehirns

Leitlinie zum hepatozellulären Karzinom

Leitliniengerechte Anwendung der Thermoablation beim hepatozellulären Karzinom

Transarterielle Chemoembolisation des hepatozellulären Karzinoms

Radiologische Aspekte der neuen deutschen S3-Leitlinie zum hepatozellulären Karzinom und biliären Karzinomen im internationalen Vergleich

Bildgebung beim intrahepatischen Cholangiokarzinom

Passend zum Thema

Synergien nutzen gegen Tumore

Darmkrebsreihenuntersuchungen zeigen EU-weit Erfolge

GI-Tumore und die Rolle von Angiogenesehemmern